SEARCH RESULTS FOR: "Tag: exel"
REFINE YOUR SEARCH:
ARTICLES/BLOGS
2019(2)
2018(3)
2017(4)
2016(3)
2015(2)
CATEGORIES
Analyst Update(1)
Buzz Stocks(5)
By the Numbers(1)
Expectational Analysis(1)
Intraday Option Activity(2)
Midday Market Check(1)
Opening View(1)
Quantitative Analysis(4)
Stock Market News(2)
Stocks On the Move(2)
Technical Analysis(2)

3/18/2019 1:06 PM
Exelixis, Inc. (NASDAQ:EXEL) shares are fresh off a new high, thanks to some upbeat analyst attention. Specifically, Morgan Stanley upgraded the biotech stock to "equal weight" from "underweight," and...
2/13/2019 10:29 AM
The shares of Exelixis Inc. (NASDAQ:EXEL) shot higher out of the gate this morning, but were last seen down 0.7% at $21.53, even though the company reported fourth-quarter earnings and revenue that ...
5/10/2018 10:19 AM
Exelixis, Inc. (NASDAQ:EXEL) stock is down 11.8% to trade at $19.13 this morning, after the biotech company's colorectal cancer drug that was tested in combination with Roche's Tecentriq failed late-...
2/23/2018 1:18 PM
ImmunoGen, Inc. (NASDAQ:IMGN) shares have been on a tear in 2018, advancing more than 75% already this year. What's more, IMGN stock could have room to run, if recent history is any indicator. Meanwhi...
1/19/2018 2:48 PM
The shares of biotech Exelixis, Inc. (NASDAQ:EXEL) -- which makes Cabometyx -- have been in a channel of higher highs and lows since early 2016, gaining 55% over the past year. Since its most recent...

Welcome to Schaeffer's Investment Research! We are a privately held provider of stock and options trading recommendations, options education, and market commentary, headquartered in Cincinnati, Ohio. Founded in 1981 by industry pioneer Bernie Schaeffer, we've since become a trusted source of research and analysis for individual investors and major financial media outlets alike.







Partner Center